

Hotgen Coronavirus 2019-nCoV

Laientest / Selbsttest mit CE0123 (1er verpackt)

Omikron-Variante (B.1.1.529, BA.2, BA.4, BA.5, BQ.1.1, BA.2.75, XBB.1.5, FLiRT) erkennen

Hersteller	Beijing Hotgen Biotech Co., Ltd.
Rep	MedNet GmbH
CE	CE0123 seit 04.08.2021
BfArM Nummer	AT1236/21
Paul-Ehrlich-Institut	evaluiert
EU List	Device #1870
HSC Common List	ja
Empfindlichkeit	96,95%
Spezifität	98,88%
Genauigkeit	98,25%

Varianten (SKU)	1er verpackt
Inhalt pro Karton/VPE	400 St. (20er x 20)
Abmessungen Karton	72,5 x 38,5 x 25,8 cm; 11,5 KG
Gebrauchsanleitung	auf Deutsch
Schulungsvideo	Über QR Code auf Einzelverpackung)





Antigen-Tests auf SARS-CoV-2 zur Eigena

die Gegenstand des Anspruchs nach §1 Satz 1 Coronavirus-Testverordnung (TestV) sin



Suchen: Alle Textspalten

Los

Aktionen

				Hersteller	
Test-ID	Name des Tests	Evaluierung PEI	Omikron-Erkennung entsprechend der Bridging-Prüfung des PEI	Name ↑	Land
AT1236/21	Coronavirus (2019-nCoV)-Antigentest-	Ja	Ja	Beijing Hotgen Biotech Co., Ltd.	CN

Declaration of Conformity

Manufacturer: Beijing Hotgen Biotech Co.,Ltd.
9th building, No.9 Tianfu Street, Biomedical Base,
Daxing District, Beijing,102600, P.R.China

European Representative: MedNet GmbH
Borkstrasse 10,48163 Muenster,Germany

Product Name: Coronavirus (2019-nCoV)-Antigentest -

Model Number: HGCG134S0101 (1T/Kit) HGCG134S0105 (5T/Kit)
HGCG134S0120 (20T/Kit) HGCG134S0140 (40T/Kit)

Notified Body: TÜV SÜD Product Service GmbH
Ridlerstraße 65, 80339 MÜNCHEN, Germany

Classification : Self-testing

Conformity Assessment Route: Annex III.6 of the directive 98/79/EC



We, herewith declare on our solo responsibility that the above-mentioned products meet the transposition into national law, the provisions of the following EC Council Directives 98/79/EC and Standards. All supporting documentations are retained under the premises of the manufacturer.

We, Beijing Hotgen Biotech Co., Ltd., is exclusively responsibility for the DOC.

Harmonized standards:

EN ISO 13485:2016; EN ISO 15223-1:2016; EN ISO 14971:2012; EN 13975:2003; EN ISO 18113-1:2011; EN ISO 18113-4:2011; EN 13612:2002; EN ISO 17511:2003; EN ISO 23640:2015; EN 13641:2002; EN 62366:2008; EN 13532:2002

(EC) Certificate(s) No. V9 089675 0006 Rev. 00

Start of CE-Marking 2021-08-05

Signature:

Name: Lin changqing

Title: General manager

Place: Beijing



To Whom It May Concern:

Statement

Regarding the product Coronavirus (2019-nCoV)-Antigentest- produced by Beijing Hotgen Biotech Co., Ltd., the following statement are especially made:

Coronavirus (2019-nCoV)-Antigentest- by our company detects N protein of SARS-CoV-2 in human anterior nasal swab samples. While the mutation of the virus found in England (B.1.1.7 strain), SouthAfrica (B.1.351 strain, Omicron variant (B.1.1.529 strain, BA.2 strain, BA.2.75 strain, BA.4 strain, BA.5 strain, BF.7 strain, BF.15 strain, BQ.1 strain, BQ.1.1 strain, XBB strain and XBB.1 strain), Brazil (P.1 strain), India (B.1.617 strain, Delta variant B.1.617.2), U.S., U.K. and Canada, etc. (FLiRT variant (KP.2 strain and KP.1.11 strain)), XE variant, EG.5 variant, Pirola (BA.2.86) variant and JN.1 variant are mainly on S protein, so our product is still effective to detect the antigen of novel coronavirus and the mutation will not affect the detection result of our product.

Beijing Hotgen Biotech Co., Ltd.

May 13th, 2024

To Whom It May Concern

Statement

Regarding the product Coronavirus(2019-nCoV)-Antigentest- produced by Beijing Hotgen Biotech Co., Ltd., the following statement are especially made:

Coronavirus(2019-nCoV)-Antigentest- by our company detects N protein of SARS-CoV-2 in human anterior nasal swab samples. While the mutation of the virus found in England (B.1.1.7 strain), SouthAfrica (B.1.351 strain, Omicron variant (B.1.1.529 strain, BA.2 strain, BA.4 strain, BA.5 strain)),Brazil (P.1 strain) , India (B.1.617 strain, Delta variant B.1.617.2) and XE variant are mainly on S protein. So our product is still effective to detect the antigen of novel coronavirus and the mutation will not affect the detection result of our product.

Beijing Hotgen Biotech Co., Ltd.

May 5th, 2022



To Whom It May Concern

Statement

Regarding the product Coronavirus(2019-nCoV)-Antigentest- produced by Beijing Hotgen Biotech Co., Ltd., the following statement are especially made:

Coronavirus(2019-nCoV)-Antigentest- by our company detects N protein of SARS-CoV-2 in human anterior nasal swab samples. While the mutation of the virus found in England (B.1.1.7 strain), SouthAfrica (B.1.351 strain, Omicron variant (B.1.1.529 strain, BA.2 strain, BA.2.75strain, BA.4 strain, BA.5 strain, BF.7 strain, BF.15 strain, BQ.1 strain, BQ.1.1 strain, XBB strain and XBB.1 strain), Brazil (P.1 strain) , India (B.1.617 strain, Delta variant B.1.617.2) and XE variant are mainly on S protein, so our product is still effective to detect the antigen of novel coronavirus and the mutation will not affect the detection result of our product.

Beijing Hotgen Biotech Co., Ltd.



To Whom It May Concern

Statement

Regarding the product Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) produced by BeijingHotgen Biotech Co., Ltd., the following statement are especially made:

Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) by our company detects N protein of SARS- CoV-2 in human nasal swab samples and throat swab samples.

While the mutation of the virus found in England (B.1.1.7 strain), SouthAfrica (B.1.351 strain, Omicron variant (B.1.1.529 strain, BA.2 strain, BA.2.75strain, BA.4 strain, BA.5 strain, BF.7 strain, BF.15 strain, BQ.1 strain, BQ.1.1 strain, XBB strain, XBB.1 strain and XBB.1.5 strain), Brazil (P.1 strain), India (B.1.617 strain, Delta variant B.1.617.2) and XE variant are mainly on S protein, so our product is still effective to detect the antigen of novel coronavirus and the mutation will not affect the detection result of our product.

Beijing Hotgen Biotech Co., Ltd.





Benannt durch/Designated by
Zentralstelle der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
www.zlg.de
ZLG-BS-245.10.07



Product Service

EC Certificate

EC Design-Examination Certificate

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex III (6)
(Devices for self-testing)

No. V9 089675 0006 Rev. 00

Manufacturer:

Beijing Hotgen Biotech Co.,Ltd

9th Building, No. 9 Tianfu Street, Biomedical Base
Daxing District
102600 Beijing
PEOPLE'S REPUBLIC OF CHINA

Product:

In Vitro diagnostic devices for self testing

The Certification Body of TÜV SÜD Product Service GmbH declares that a design examination has been carried out on the respective devices in accordance with IVDD Annex III (6). The design of the devices conforms to the requirements of this Directive. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:V9 089675 0006 Rev. 00](http://www.tuvsud.com/ps-cert?q=cert:V9_089675_0006_Rev.00)

Report No.:

BJ21071201

Valid from:

2021-08-04

Valid until:

2024-05-26

Date,

2021-08-04

Christoph Dicks
Head of Certification/Notified Body



Benannt durch/Designated by
 Zentralstelle der Länder
 für Gesundheitsschutz
 bei Arzneimitteln und
 Medizinprodukten
 www.zlg.de
 ZLG-BS-245.10.07



Product Service

EC Certificate

EC Design-Examination Certificate
 Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex III (6)
 (Devices for self-testing)

No. V9 089675 0006 Rev. 00

Model(s): **Coronavirus (2019-nCoV)-Antigentest-**

Facility(ies): Beijing Hotgen Biotech Co.,Ltd
 9th Building, No. 9 Tianfu Street, Biomedical Base, Daxing District,
 102600 Beijing, PEOPLE'S REPUBLIC OF CHINA

Model Name:	REF number:
Coronavirus (2019-nCoV)-Antigentest-	HGCG134S0101
Coronavirus (2019-nCoV)-Antigentest-	HGCG134S0105
Coronavirus (2019-nCoV)-Antigentest-	HGCG134S0120
Coronavirus (2019-nCoV)-Antigentest-	HGCG134S0140

